Opus Genetics (IRD) said that the FDA has granted Fast Track designation for Phentolamine Ophthalmic Solution 0.75% as a ...

FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night ...

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 ...

Opus Genetics, Inc. announced the dosing of the first pediatric patient in its Phase 1/2 trial for OPGx-LCA5, a gene therapy targeting Leber congenital amaurosis (LCA). Initial results from this ...

Opus Genetics (IRD) announced that the first pediatric patient was dosed in its ongoing Phase 1/2 clinical trial evaluating OPGx-LCA5, its ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever 15.0% of Opus Genetics shares are held by institutional investors.

(RTTNews) - Opus Genetics, Inc. (IRD), a clinical-stage ophthalmic biotechnology company, on Tuesday announced that the first pediatric patient has been dosed in its global Phase 1/2 clinical ...

Opus Genetics, Inc. (IRD) stock price is 1.17 and Opus Genetics, Inc. (IRD) 10-day simple moving average is 1.18. Opus Genetics, Inc. (IRD) stock price is 1.17 and Opus Genetics, Inc. (IRD ...

Opus Genetics (IRD) announced completion of enrollment in the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% ...

Opus Genetics is a clinical-stage ophthalmic biotechnology company developing gene therapies to treat patients with IRDs and other treatments for ophthalmic disorders. The pipeline includes adeno ...